BioSpace News Archive

Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia”, or the “Company”), a medical research company with mental health clinics providing innovative ketamine and psilocybin treatments for depression and related disorders

TPG and AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of their previously announced acquisition of OneOncology, a network of leading oncology practices.

Shionogi & Co., Ltd. today announced the first participant has been enrolled in Japan in its global Phase 3 study, Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post Exposure Prophylaxis (SCORPIO-PEP).

NRx Pharmaceuticals, Inc. today announced that it has closed its previously announced registered direct offering for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that positive results from the global Phase III COMMODORE 1 and 2 studies, evaluating the efficacy and safety of crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, compared to eculizumab.

T2 Biosystems, Inc. (NASDAQ:TTOO) today announced a collaborative relationship with Vanderbilt University Medical Center’s (VUMC) Learning Healthcare System (LHS) Platform, which unites clinical research and clinical operations to evaluate and implement new approaches to care that can improve the health of patients and the community.

Rallybio Corporation (Nasdaq: RLYB) today announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28.

Marius Pharmaceuticals announced that its U.S. patents related to KYZATREX™, No. 11590146B2 and No. 11617758B2, are now listed in the U.S. Food and Drug Administration publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book.”.

The global stem cell therapy market size was estimated at USD 11.22 billion in 2022 and it is projected to reach around USD 31.41 billion by 2030 and growing at a compound annual growth rate (CAGR) of 13.73% during the forecast period 2023 to 2030.

The board of directors of Abbott declared a quarterly common dividend of 51 cents per share.